1314910-43-4 Usage
General Description
2-(azetidin-3-ylidene)acetonitrile (hydrochloride) is a chemical compound that is categorized under the class of organic compounds known as nitriles. Nitriles are compounds having a triple bond between a carbon atom and a nitrogen atom. The compound contains an azetidine, a saturated ring with three carbon atoms and one nitrogen atom. As the hydrochloride form, it's an ionic compound that includes a chloride ion. This form often results in increased solubility, therefore improving bioavailability for pharmaceutical applications. This chemical needs to be handled with care due to its reactivity. However, specific data about its uses, safety, effects or industrial applications are not widely documented.
Check Digit Verification of cas no
The CAS Registry Mumber 1314910-43-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,4,9,1 and 0 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1314910-43:
(9*1)+(8*3)+(7*1)+(6*4)+(5*9)+(4*1)+(3*0)+(2*4)+(1*3)=124
124 % 10 = 4
So 1314910-43-4 is a valid CAS Registry Number.
1314910-43-4Relevant articles and documents
PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR
-
, (2022/03/02)
The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR
-
Paragraph 0102-0103, (2019/08/22)
This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF
-
Page/Page column 10; 11, (2016/09/22)
The present invention provides processes for the preparation of baricitinib of Formula I and an intermediate of Formula V. The present invention also provides the use of the intermediate of Formula V for the preparation of baricitinib.
